Maternal Psychiatric Conditions, Treatment With Selective Serotonin Reuptake Inhibitors, and Neurodevelopmental Disorders.
Autism Spectrum Disorder
/ drug therapy
Case-Control Studies
Child
Female
Humans
Mothers
Neurodevelopmental Disorders
/ chemically induced
Pregnancy
Pregnancy Complications
/ drug therapy
Prenatal Exposure Delayed Effects
/ epidemiology
Selective Serotonin Reuptake Inhibitors
/ adverse effects
United States
/ epidemiology
Antidepressants
Autism
Neurodevelopmental Disorders
Perinatal Exposure
Psychiatric Conditions
SSRIs
Journal
Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264
Informations de publication
Date de publication:
15 08 2021
15 08 2021
Historique:
received:
19
01
2021
revised:
06
04
2021
accepted:
07
04
2021
pubmed:
13
6
2021
medline:
11
8
2021
entrez:
12
6
2021
Statut:
ppublish
Résumé
This study aims to clarify relationships of maternal psychiatric conditions and selective serotonin reuptake inhibitor (SSRI) use during preconception and pregnancy with risk of neurodevelopmental disorders in offspring. We used data from the Study to Explore Early Development, a multisite case-control study conducted in the United States among children born between 2003 and 2011. Final study group classifications of autism spectrum disorder (ASD) (n = 1367), developmental delays or disorders (DDs) (n = 1750), and general population controls (n = 1671) were determined by an in-person standardized developmental assessment. Maternal psychiatric conditions and SSRI use during pregnancy were ascertained from both self-report and medical records. We used logistic regression to evaluate associations of ASD and DDs (vs. population controls) with maternal psychiatric conditions and SSRI treatment in pregnancy. To reduce confounding by indication, we also examined SSRI associations in analyses restricted to mothers with psychiatric conditions during pregnancy. Psychiatric conditions and SSRI use during pregnancy were significantly more common among mothers of children with either ASD or DDs than among population controls. Odds of ASD were similarly elevated among mothers with psychiatric conditions who did not use SSRIs during pregnancy (adjusted odds ratio 1.81, 95% confidence interval 1.44-2.27) as in mothers who did use SSRIs (adjusted odds ratio 2.05, 95% confidence interval 1.50-2.80). Among mothers with psychiatric conditions, SSRI use was not significantly associated with ASD in offspring (adjusted odds ratio 1.14, 95% confidence interval 0.80-1.62). Primary findings for DDs exhibited similar relationships to those observed with ASD. Maternal psychiatric conditions but not use of SSRIs during pregnancy were associated with increased risk of neurodevelopmental disorders in offspring.
Sections du résumé
BACKGROUND
This study aims to clarify relationships of maternal psychiatric conditions and selective serotonin reuptake inhibitor (SSRI) use during preconception and pregnancy with risk of neurodevelopmental disorders in offspring.
METHODS
We used data from the Study to Explore Early Development, a multisite case-control study conducted in the United States among children born between 2003 and 2011. Final study group classifications of autism spectrum disorder (ASD) (n = 1367), developmental delays or disorders (DDs) (n = 1750), and general population controls (n = 1671) were determined by an in-person standardized developmental assessment. Maternal psychiatric conditions and SSRI use during pregnancy were ascertained from both self-report and medical records. We used logistic regression to evaluate associations of ASD and DDs (vs. population controls) with maternal psychiatric conditions and SSRI treatment in pregnancy. To reduce confounding by indication, we also examined SSRI associations in analyses restricted to mothers with psychiatric conditions during pregnancy.
RESULTS
Psychiatric conditions and SSRI use during pregnancy were significantly more common among mothers of children with either ASD or DDs than among population controls. Odds of ASD were similarly elevated among mothers with psychiatric conditions who did not use SSRIs during pregnancy (adjusted odds ratio 1.81, 95% confidence interval 1.44-2.27) as in mothers who did use SSRIs (adjusted odds ratio 2.05, 95% confidence interval 1.50-2.80). Among mothers with psychiatric conditions, SSRI use was not significantly associated with ASD in offspring (adjusted odds ratio 1.14, 95% confidence interval 0.80-1.62). Primary findings for DDs exhibited similar relationships to those observed with ASD.
CONCLUSIONS
Maternal psychiatric conditions but not use of SSRIs during pregnancy were associated with increased risk of neurodevelopmental disorders in offspring.
Identifiants
pubmed: 34116791
pii: S0006-3223(21)01218-X
doi: 10.1016/j.biopsych.2021.04.002
pmc: PMC8504533
mid: NIHMS1709035
pii:
doi:
Substances chimiques
Serotonin Uptake Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
253-262Subventions
Organisme : NCBDD CDC HHS
ID : U10 DD000180
Pays : United States
Organisme : NCBDD CDC HHS
ID : U10 DD000181
Pays : United States
Organisme : NCBDD CDC HHS
ID : U10 DD000184
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD087915
Pays : United States
Organisme : NCBDD CDC HHS
ID : U10 DD000182
Pays : United States
Organisme : NCBDD CDC HHS
ID : U10 DD000183
Pays : United States
Organisme : NCBDD CDC HHS
ID : U01 DD001210
Pays : United States
Organisme : NCBDD CDC HHS
ID : U01 DD000498
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Society of Biological Psychiatry. All rights reserved.
Références
J Am Acad Child Adolesc Psychiatry. 1991 May;30(3):471-8
pubmed: 1829081
J Autism Dev Disord. 2015 May;45(5):1271-80
pubmed: 25348175
Psychol Med. 2017 Dec;47(16):2787-2796
pubmed: 28528584
BMJ. 2017 Jul 19;358:j2811
pubmed: 28724519
Pediatrics. 2014 May;133(5):e1241-8
pubmed: 24733881
Br J Psychiatry. 2014 Aug;205(2):95-102
pubmed: 25252317
J Clin Pharmacol. 2011 Feb;51(2):264-70
pubmed: 20663997
Neurogenetics. 2009 Jul;10(3):209-16
pubmed: 19184136
JAMA Psychiatry. 2017 Oct 1;74(10):1031-1038
pubmed: 28700807
Birth Defects Res A Clin Mol Teratol. 2016 Nov;106(11):927-934
pubmed: 27891779
JAMA Pediatr. 2016 Feb;170(2):117-24
pubmed: 26660917
J Autism Dev Disord. 2000 Jun;30(3):205-23
pubmed: 11055457
J Autism Dev Disord. 2012 Oct;42(10):2121-40
pubmed: 22350336
Brain Pathol. 2007 Oct;17(4):434-47
pubmed: 17919129
Mol Brain. 2019 Apr 1;12(1):29
pubmed: 30935412
Emerg Themes Epidemiol. 2018 Aug 16;15:12
pubmed: 30147744
Am J Epidemiol. 2005 May 15;161(10):916-25; discussion 926-8
pubmed: 15870155
J Child Psychol Psychiatry. 2005 Sep;46(9):963-71
pubmed: 16108999
Clin Epidemiol. 2013 Nov 15;5:449-59
pubmed: 24255601
Mol Psychiatry. 2015 Jun;20(6):727-34
pubmed: 25155880
Neurosci Biobehav Rev. 2018 Feb;85:102-116
pubmed: 28472631
J Am Acad Child Adolesc Psychiatry. 2016 May;55(5):359-66
pubmed: 27126849
Am J Psychiatry. 1999 Apr;156(4):557-63
pubmed: 10200734
JAMA Psychiatry. 2016 Nov 1;73(11):1163-1170
pubmed: 27732704
Gen Hosp Psychiatry. 2009 Sep-Oct;31(5):403-13
pubmed: 19703633
Autism Res. 2012 Jun;5(3):160-79
pubmed: 22495912
BMJ. 2015 Jul 08;351:h3190
pubmed: 26156519
Arch Gen Psychiatry. 2011 Nov;68(11):1104-12
pubmed: 21727247
JAMA. 2017 Apr 18;317(15):1544-1552
pubmed: 28418480
J Child Psychol Psychiatry. 2019 Apr;60(4):356-376
pubmed: 30515808
Biol Psychiatry. 2019 Oct 15;86(8):587-598
pubmed: 31182215
J Autism Dev Disord. 2014 Oct;44(10):2558-67
pubmed: 24803368
CNS Drugs. 2016 Jun;30(6):499-515
pubmed: 27138915
Transl Psychiatry. 2016 Jan 05;6:e708
pubmed: 26731445
Clin Ther. 2009 Jun;31 Pt 1:1426-53
pubmed: 19698902
Pediatrics. 2010 Mar;125(3):e600-8
pubmed: 20176667
J Autism Dev Disord. 2013 Aug;43(8):1946-55
pubmed: 23263770
Lancet. 2013 Apr 20;381(9875):1371-1379
pubmed: 23453885
MMWR Surveill Summ. 2018 Apr 27;67(6):1-23
pubmed: 29701730
J Child Psychol Psychiatry. 2016 Jun;57(6):759-69
pubmed: 26714925
N Engl J Med. 2013 Dec 19;369(25):2406-15
pubmed: 24350950
Psychol Med. 1998 Mar;28(2):385-95
pubmed: 9572095
J Autism Dev Disord. 1994 Oct;24(5):659-85
pubmed: 7814313
Pediatrics. 2008 May;121(5):e1357-62
pubmed: 18450879
Pharmacopsychiatry. 2009 May;42(3):95-100
pubmed: 19452377
BMJ. 2017 Sep 6;358:j3668
pubmed: 28877907
JAMA. 2017 Apr 18;317(15):1553-1562
pubmed: 28418479
BMC Med. 2018 Jan 15;16(1):6
pubmed: 29332605
Genome Med. 2009 Oct 30;1(10):102
pubmed: 19886976
BMJ. 2013 Apr 19;346:f2059
pubmed: 23604083
J Abnorm Child Psychol. 2019 Apr;47(4):731-740
pubmed: 30128718
Annu Rev Public Health. 2017 Mar 20;38:81-102
pubmed: 28068486
Disabil Health J. 2016 Jul;9(3):544-51
pubmed: 26917104
CNS Drugs. 2012 Jul 1;26(7):e1-14
pubmed: 22712699
Clin Epidemiol. 2018 Nov 01;10:1599-1612
pubmed: 30464639
Arch Womens Ment Health. 2016 Dec;19(6):969-977
pubmed: 27178125